Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.

Left ventricular (LV) dysfunction c-kit-positive, lineage-negative cardiac stem cells (CSC) improving post-infarction when given to animals. We conducted an experiment phase 1 (Stem Cell Infusion in Patients with ischemic cardiomyopathy [Scipio]) from autologous CSC for the treatment of heart failure due to ischemic heart disease.In trial stage A Scipio, patients with post-infarction LV dysfunction (ejection fraction [EF] ≤ 40%) prior to coronary artery bypass grafting were consecutively enrolled in the treatment and control groups. In stage B, patients were randomly assigned to treatment or control groups in a ratio of 2: 3 by using the block scheme of computer-generated randomization. 1 million autologous CSC given by intracoronary infusion at an average of 113 days (SE 4) after surgery; untreated controls.

Although this study is an open label, echocardiographic analysis did not know the duties of the group. The primary endpoint was a short-term security of CSC and the secondary endpoint was efficacy. A per-protocol analysis were used. This study is registered with ClinicalTrials.gov, number NCT00474461.This study is still in progress. 16 patients were assigned to the treatment group and seven for the control group; no side effects were reported related CSC.

On 14 CSC-treated patients were analyzed, LVEF increased from 30 · 3% (SE 1 · 9) before CSC infusion to 38 · 5% (2 · 8) at 4 months after infusion (p = 0 · 001). In contrast, the seven control patients, as long as the appropriate time interval, LVEF did not change (30 · 1% [2 · 4] at 4 months after CABG vs 30 · 2% [2 · 5] at 8 months after CABG). Importantly, CSC healthful effects are even more pronounced in the first year in eight patients (eg, LVEF increased by 12 · 3 unit ejection fraction [2 · 1] vs baseline, p = 0 · 0007).

In seven patients treated in whom cardiac MRI can be done, infarct size decreased from 32 · 6 g (6 · 3) by 7 · 8 g (1 · 7; 24%) at 4 months (p = 0 · 004) and 9 · 8 g (3 · 5; 30%) at 1 year (p = 0 · 04) .This preliminary results in patients with very encouraging. They suggest that intracoronary infusion of autologous CSC effective in improving LV systolic function and reduced infarct size in patients with heart failure after myocardial infarction, and warrant further, larger, phase 2 studies.University of Louisville Research Foundation and the National Institutes of Health ,

D-Luciferin, sodium salt

10102-2 1G
EUR 714
Description: Minimum order quantity: 1 unit of 1G

D-Luciferin, Sodium Salt

7902-100
EUR 120

D-Luciferin, Sodium Salt

7902-10G
EUR 2409

D-Luciferin, Sodium Salt

7902-10PK
EUR 2763

D-Luciferin, Sodium Salt

7902-1G
EUR 354

D-Luciferin, Sodium Salt

7902-25G Ask for price

D-Luciferin, Sodium Salt

7902-3PK
EUR 925

D-Luciferin, Sodium Salt

7902-50G Ask for price

D-Luciferin, Sodium Salt

7902-5PK
EUR 1496

D-Luciferin sodium salt

B8311-10 10 mg
EUR 131

D-Luciferin sodium salt

B8311-200 200 mg
EUR 699

D-Luciferin sodium salt

B8311-50 50 mg
EUR 293

D-Luciferin (sodium salt)

HY-12591 50mg
EUR 153

D-Luciferin, potassium salt

10101 10MG
EUR 112
Description: Minimum order quantity: 1 unit of 10MG

D-Luciferin, potassium salt

10101-1 50MG
EUR 234
Description: Minimum order quantity: 1 unit of 50MG

D-Luciferin, potassium salt

10101-2 1G
EUR 714
Description: Minimum order quantity: 1 unit of 1G

D-Luciferin, Potassium Salt

D0510-010 100mg
EUR 185

D-Luciferin, Potassium Salt

D0510-050 500mg
EUR 504

D-Luciferin, Potassium Salt

D0510-100 1g
EUR 847

D-Luciferin, Potassium Salt

7903-100
EUR 120

D-Luciferin, Potassium Salt

7903-10G
EUR 2409

D-Luciferin, Potassium Salt

7903-10PK
EUR 2763

D-Luciferin, Potassium Salt

7903-1G
EUR 354

D-Luciferin, Potassium Salt

7903-25G Ask for price

D-Luciferin, Potassium Salt

7903-3PK
EUR 925

D-Luciferin, Potassium Salt

7903-50G Ask for price

D-Luciferin, Potassium Salt

7903-5PK
EUR 1496

D-Luciferin potassium salt

HY-12591B 50mg
EUR 153

D-Luciferin, sodium salt *CAS#: 103404-75-7*

12509 25 mg
EUR 115
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 41105331

D-Luciferin, sodium salt *CAS#: 103404-75-7*

12510 100 mg
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 41105331

D-Luciferin, sodium salt *CAS#: 103404-75-7*

12511 1 g
EUR 528
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 41105331

EZSolution? D-Luciferin, Potassium Salt

B3001-set
EUR 370

Brite-Light? D-Luciferin, Potassium Salt

B3000-10PK
EUR 2268

Brite-Light? D-Luciferin, Potassium Salt

B3000-1G
EUR 327

Brite-Light? D-Luciferin, Potassium Salt

B3000-5PK
EUR 1300

D-Luciferin

B6040-10 10 mg
EUR 131
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP.

D-Luciferin

B6040-200 200 mg
EUR 699
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP.

D-Luciferin

B6040-50 50 mg
EUR 293
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP.

D-Luciferin

HY-12591A 10mg
EUR 108

D-Luciferin

GP9319-100MG 100 mg
EUR 221

D-Luciferin

GP9319-10MG 10 mg
EUR 70

D-Luciferin

GP9319-25MG 25 mg
EUR 110

D-Luciferin

GP9319-50MG 50 mg
EUR 150

D-Luciferin, potassium salt *CAS#: 115144-35-9*

12505 25 mg
EUR 115
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 41105331

D-Luciferin, potassium salt *CAS#: 115144-35-9*

12506 100 mg
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 41105331

D-Luciferin, potassium salt *CAS#: 115144-35-9*

12507 1 g
EUR 263
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 41105331

D-Luciferin acetate

12516 5 mg
EUR 219
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 41105331

Estradiol 17-(?-D-Glucuronide) (sodium salt)

C3840-10 10 mg
EUR 206
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 17-(?-D-Glucuronide) (sodium salt)

C3840-25 25 mg
EUR 338
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 17-(?-D-Glucuronide) (sodium salt)

C3840-5 5 mg
EUR 132
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 17-(?-D-Glucuronide) (sodium salt)

C3840-50 50 mg
EUR 502
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes.

Estradiol 3-(?-D-Glucuronide) (sodium salt)

C3897-1 1 mg
EUR 118
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

Estradiol 3-(?-D-Glucuronide) (sodium salt)

C3897-10 10 mg
EUR 527
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

Estradiol 3-(?-D-Glucuronide) (sodium salt)

C3897-25 25 mg
EUR 1073
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

Estradiol 3-(?-D-Glucuronide) (sodium salt)

C3897-5 5 mg
EUR 306
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2].

Methyl beta-D-glucuronide sodium salt

GC4190-1G 1 g
EUR 229

Methyl beta-D-glucuronide sodium salt

GC4190-250MG 250 mg
EUR 110

D-Glucuronic acid sodium salt monohydrate

GC8431-100G 100 g
EUR 126

D-Glucuronic acid sodium salt monohydrate

GC8431-250G 250 g
EUR 229

D-Glucuronic acid sodium salt monohydrate

GC8431-25G 25 g
EUR 70

D-Glucuronic acid sodium salt monohydrate

GC8431-5G 5 g
EUR 46

D-Glucosamine 2-sulfate sodium salt

GC9126-25MG 25 mg
EUR 61

D-Glucuronic acid, sodium salt, monohydrate

GB0483 5g
EUR 107.42
  • Product category: Biochemicals/Carbohydrates/Sugars

D-Luciferin (Free acid)

2779-1000
EUR 338

D-Luciferin (Free acid)

2779-250
EUR 175

D-Luciferin (Free acid)

2779-500
EUR 251

D-Luciferin (Free acid)

2779-5000
EUR 1273

D-Luciferin, free acid

10100 10MG
EUR 112
Description: Minimum order quantity: 1 unit of 10MG

D-Luciferin, free acid

10100-1 50MG
EUR 234
Description: Minimum order quantity: 1 unit of 50MG

D-Luciferin, free acid

10100-2 1G
EUR 714
Description: Minimum order quantity: 1 unit of 1G

Thyroxine (Sodium salt)

30-AT52 1 gram
EUR 352
Description: High purity Thyroxine sodium salt

Triiodothyronine (Sodium salt)

30-AT53 1 gram
EUR 849
Description: High purity (>99%) Triiodothyronine sodium salt

Nigericin sodium salt

2096-25
EUR 387

Nigericin sodium salt

2096-5
EUR 147

NADP, sodium salt

2737-100
EUR 153

NADP, sodium salt

2737-1000
EUR 784

NADP, sodium salt

2737-500
EUR 457

Resazurin, sodium salt

10054 10MG
EUR 148
Description: Minimum order quantity: 1 unit of 10MG

Novobiocin Sodium Salt

B1526-1G
EUR 109

Novobiocin Sodium Salt

B1526-5G
EUR 240

Cefazolin Sodium Salt

B1530-1G
EUR 142

Cefazolin Sodium Salt

B1530-5G
EUR 359

Cefoxitin Sodium Salt

B1892-1G
EUR 185

Cefoxitin Sodium Salt

B1892-500
EUR 131

Cefoxitin Sodium Salt

B1892-5G
EUR 577

Azlocillin sodium salt

B1893-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: Azlocillin is an acylampicillin with a broad spectrum against bacteria.

Azlocillin sodium salt

B1893-50 50 mg
EUR 128
Description: Azlocillin is an acylampicillin with a broad spectrum against bacteria.

Azlocillin sodium salt

B1893-S Evaluation Sample
EUR 81
Description: Azlocillin is an acylampicillin with a broad spectrum against bacteria.

Sulfamerazine sodium salt

B3430-100000 100 g
EUR 137
Description: Sulfamerazine Sodium is a sulfonamide antibacterial.

Sulfamerazine sodium salt

B3430-50000 50 g
EUR 110
Description: Sulfamerazine Sodium is a sulfonamide antibacterial.

GSK2190915 sodium salt

B4905-10 10 mg
EUR 429

GSK2190915 sodium salt

B4905-5 5 mg
EUR 277

GSK2190915 sodium salt

B4905-5.1 10 mM (in 1mL DMSO)
EUR 380

GSK2190915 sodium salt

B4905-50 50 mg
EUR 1549

Ischemin sodium salt

B4917-10 10 mg
EUR 268

Ischemin sodium salt

B4917-50 50 mg
EUR 973

Proglumide sodium salt

B5121-100 100 mg
EUR 139

Proglumide sodium salt

B5121-5.1 10 mM (in 1mL DMSO)
EUR 150
Scroll to Top